<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aptamer Group Plc — News on 6ix</title>
<link>https://6ix.com/company/aptamer-group-plc</link>
<description>Latest news and press releases for Aptamer Group Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aptamer-group-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835df3a78dffbe2df1257db.webp</url>
<title>Aptamer Group Plc</title>
<link>https://6ix.com/company/aptamer-group-plc</link>
</image>
<item>
<title>Result of Retail Offer and Posting of Notice of GM</title>
<link>https://6ix.com/company/aptamer-group-plc/news/result-of-retail-offer-and-posting-of-notice-of-gm</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/result-of-retail-offer-and-posting-of-notice-of-gm</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>Aptamer Group plc announced the results of its Retail Offer, which raised approximately £274,000 before expenses, resulting in the issue of 45,665,573 Retail Offer Shares at 0.6p each. This brings the total raised from the Placing, Subscription, and Retail Offer to approximately £4.5 million, with approximately £3.1 million of this amount conditional on resolutions passed at a General Meeting scheduled for 13 April 2026. A circular and notice of the General Meeting have been posted to shareholde</description>
</item>
<item>
<title>Retail Offer to raise up to £0.5 million</title>
<link>https://6ix.com/company/aptamer-group-plc/news/retail-offer-to-raise-up-to-pound05-million-1</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/retail-offer-to-raise-up-to-pound05-million-1</guid>
<pubDate>Thu, 26 Mar 2026 07:05:00 GMT</pubDate>
<description>Aptamer Group plc is launching a retail offer to raise up to £0.5 million by issuing new ordinary shares at 0.6 pence each, with participants receiving one warrant for every three shares subscribed. This retail offer is in addition to a conditional placing and subscription that has already raised approximately £4.275 million. The net proceeds from the retail offer will be used for the same purposes as the funds raised from the placing and subscription. Admission of the retail offer shares to tra</description>
</item>
<item>
<title>Interim Results and Notice of Investor Webinar</title>
<link>https://6ix.com/company/aptamer-group-plc/news/interim-results-and-notice-of-investor-webinar</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/interim-results-and-notice-of-investor-webinar</guid>
<pubDate>Wed, 25 Mar 2026 07:10:00 GMT</pubDate>
<description>Aptamer Group plc reported interim results for the six months ended December 31, 2025, showing a 27% increase in revenue to £0.83 million, alongside a reduced adjusted EBITDA loss of £1.0 million. The company successfully raised £1.8 million in July 2025, maintaining a cash balance of £1.5 million at period-end, providing a runway through Q2 2027. Significant strategic progress includes out-licensing enzyme-modulating Optimers, advancing Unilever programs, and securing a £360,000 contract in the</description>
</item>
<item>
<title>Launch of targeted radiopharmaceutical programme</title>
<link>https://6ix.com/company/aptamer-group-plc/news/launch-of-targeted-radiopharmaceutical-programme</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/launch-of-targeted-radiopharmaceutical-programme</guid>
<pubDate>Wed, 18 Mar 2026 07:00:00 GMT</pubDate>
<description>Aptamer Group plc has launched a new targeted radiopharmaceutical programme in collaboration with Radiopharmium Ltd, aiming to build a proprietary pipeline of four radiotherapy assets with in vivo data expected by the end of 2026. This initiative focuses on three high-value clinical indications, leveraging Aptamer's Optimer® platform to address limitations in current targeting technologies within the approximately US$7.5 billion radiopharmaceuticals market. Comparative testing demonstrated that </description>
</item>
<item>
<title>Technical Feasibility for Pathogen Detector</title>
<link>https://6ix.com/company/aptamer-group-plc/news/technical-feasibility-for-pathogen-detector</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/technical-feasibility-for-pathogen-detector</guid>
<pubDate>Tue, 17 Feb 2026 07:00:00 GMT</pubDate>
<description>Aptamer Group plc has successfully completed Phase 1 of its collaboration with Metir plc, achieving technical feasibility for novel Optimer® binders targeting *Cryptosporidium parvum* oocysts for Metir's real-time Pathogen Detector platform. This milestone, completed on time and budget, confirms the feasibility of developing high-affinity binders with no material technical barriers identified, paving the way for Phase 2 development expected in Q2 2026. Metir aims for a Proof of Concept device in</description>
</item>
<item>
<title>Optimer® Technology in Launched Library Prep Kit</title>
<link>https://6ix.com/company/aptamer-group-plc/news/optimerr-technology-in-launched-library-prep-kit</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/optimerr-technology-in-launched-library-prep-kit</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>Aptamer Group plc announced that Twist Bioscience Corporation has launched its new TrueAmp Library Preparation Kit, which incorporates Aptamer's proprietary Optimer® binders as an enabling technology for room temperature stability. This partnership, stemming from a non-exclusive license agreement signed in December 2025, strategically combines Twist Bioscience's synthetic biology expertise with Aptamer's Optimer® technology to enhance the rapidly expanding next-generation sequencing market. The </description>
</item>
<item>
<title>Contract wins and first cash licensing receipts</title>
<link>https://6ix.com/company/aptamer-group-plc/news/contract-wins-and-first-cash-licensing-receipts</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/contract-wins-and-first-cash-licensing-receipts</guid>
<pubDate>Thu, 29 Jan 2026 07:00:00 GMT</pubDate>
<description>Aptamer Group plc announced significant commercial progress with £190,000 in new fee-for-service contracts and extensions, including repeat business from top-tier pharmaceutical partners, bringing the FY26 order book to over £2.1 million. Additionally, the company received its first cash licensing receipts of £80,000 from a hot-start PCR Optimer® licence, with an upfront payment of £75,000 expected to contribute passive income equivalent to approximately 15% of annual overhead over three years. </description>
</item>
<item>
<title>Trading update - Media comment and speculation</title>
<link>https://6ix.com/company/aptamer-group-plc/news/trading-update-media-comment-and-speculation</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/trading-update-media-comment-and-speculation</guid>
<pubDate>Wed, 07 Jan 2026 16:04:00 GMT</pubDate>
<description>Aptamer Group plc has issued a trading update to address media comment and speculation, confirming that its current cash position provides a runway through to June 2027, consistent with previous statements. This update reassures investors regarding the company's financial stability and operational outlook.
Disclaimer*</description>
</item>
<item>
<title>Half Year Trading Update</title>
<link>https://6ix.com/company/aptamer-group-plc/news/half-year-trading-update-25</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/half-year-trading-update-25</guid>
<pubDate>Wed, 07 Jan 2026 07:00:00 GMT</pubDate>
<description>Aptamer Group plc reported a 27% increase in revenue to £0.83 million for the six months ending December 31, 2025, with an FY26 fee-for-service order book exceeding £2.0 million and a sales pipeline of £3.1 million. The company has secured multiple licensing agreements, including with Twist Bioscience and Alphazyme, with initial commercial sales anticipated in the second half of FY26. Significant progress has been made with partners like Unilever and a top 3 pharmaceutical company for radioligan</description>
</item>
<item>
<title>Aptamer signs licensing agreement with Alphazyme</title>
<link>https://6ix.com/company/aptamer-group-plc/news/aptamer-signs-licensing-agreement-with-alphazyme</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/aptamer-signs-licensing-agreement-with-alphazyme</guid>
<pubDate>Tue, 23 Dec 2025 07:00:00 GMT</pubDate>
<description>Aptamer Group plc has signed a non-exclusive OEM licensing agreement with Alphazyme LLC for an enzyme-modulating Optimer® to be used in hot-start PCR and next-generation sequencing applications. This agreement includes royalty payments on product sales, milestone payments, and a manufacturing supply agreement, with Aptamer Group manufacturing the Optimer® for Alphazyme. This deal, which follows an initial development agreement signed in June 2024, demonstrates commercial validation of Aptamer's </description>
</item>
<item>
<title>Licensing agreement with Twist Bioscience</title>
<link>https://6ix.com/company/aptamer-group-plc/news/licensing-agreement-with-twist-bioscience</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/licensing-agreement-with-twist-bioscience</guid>
<pubDate>Tue, 16 Dec 2025 10:34:00 GMT</pubDate>
<description>Aptamer Group plc has entered into a non-exclusive licensing agreement with Twist Bioscience, granting them rights to use a proprietary enzyme-modulating Optimer® binder in next-generation sequencing and hot-start PCR products. This partnership allows Aptamer to leverage its intellectual property within the rapidly expanding NGS market, projected to reach $23.6 billion by 2029. Aptamer will supply the Optimer® binder to Twist Bioscience, aiming to generate revenue through upfront payments and on</description>
</item>
<item>
<title>Results of 2025 Annual General Meeting</title>
<link>https://6ix.com/company/aptamer-group-plc/news/results-of-2025-annual-general-meeting-2</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/results-of-2025-annual-general-meeting-2</guid>
<pubDate>Thu, 27 Nov 2025 13:01:00 GMT</pubDate>
<description>Aptamer Group plc announced that all resolutions were duly passed at its Annual General Meeting held on November 27, 2025. The company, a developer of synthetic binders for the life science industry, confirmed that details of the resolutions were provided in the Notice of Meeting sent to shareholders on November 3, 2025, and full poll results will be available on the company's website.
Disclaimer*</description>
</item>
<item>
<title>AGM Statement</title>
<link>https://6ix.com/company/aptamer-group-plc/news/agm-statement-111</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/agm-statement-111</guid>
<pubDate>Thu, 27 Nov 2025 07:00:00 GMT</pubDate>
<description>Aptamer Group plc reported sustained commercial momentum and strategic progress, highlighted by significant contract wins with three top 10 global pharmaceutical companies, contributing to an order book of £1.95 million for FY26 with seven months remaining, which provides confidence that revenue will materially exceed the prior year. The company launched a Biomarker Discovery Service in August 2025 and advanced key collaborations, while a July 2025 placing successfully raised £1.8 million for op</description>
</item>
<item>
<title>Strong contract wins build commercial momentum</title>
<link>https://6ix.com/company/aptamer-group-plc/news/strong-contract-wins-build-commercial-momentum</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/strong-contract-wins-build-commercial-momentum</guid>
<pubDate>Fri, 14 Nov 2025 07:00:00 GMT</pubDate>
<description>Aptamer Group plc announced strong commercial momentum with two new contract wins totaling £192,000, bringing its binding FY26 order book to £1.95 million. This includes a fourth engagement with a top 5 global pharmaceutical company for neurological sample bioanalysis and a new contract for acute myeloid leukaemia diagnostics. The company expects full year revenue to exceed the prior year, driven by its dual revenue strategy of fee-for-service contracts and strategic IP retention for future roya</description>
</item>
<item>
<title>New contract with top five pharma company</title>
<link>https://6ix.com/company/aptamer-group-plc/news/new-contract-with-top-five-pharma-company</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/new-contract-with-top-five-pharma-company</guid>
<pubDate>Tue, 04 Nov 2025 07:00:00 GMT</pubDate>
<description>New contract with top five pharma company.</description>
</item>
<item>
<title>Posting of Annual Report and Notice of AGM</title>
<link>https://6ix.com/company/aptamer-group-plc/news/posting-of-annual-report-and-notice-of-agm-92</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/posting-of-annual-report-and-notice-of-agm-92</guid>
<pubDate>Mon, 03 Nov 2025 07:00:00 GMT</pubDate>
<description>Aptamer Group PLC announced that the Annual Report and Accounts for the year ended 30 June 2025, and the Notice of the 2025 Annual General Meeting (AGM) have been posted to shareholders and are available on the company website. The AGM will be held in person at Windmill House, Innovation Way, York, YO10 5BR at 11:00 GMT on 27 November 2025. No new information will be presented at the meeting. The results of voting on all resolutions at the AGM will be announced to the London Stock Exchange.
</description>
</item>
<item>
<title>Full Year Results for the 12mths to 30 June 2025</title>
<link>https://6ix.com/company/aptamer-group-plc/news/full-year-results-for-the-12mths-to-30-june-2025</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/full-year-results-for-the-12mths-to-30-june-2025</guid>
<pubDate>Tue, 14 Oct 2025 06:00:00 GMT</pubDate>
<description>Aptamer Group PLC announced its full year results for the twelve months ended 30 June 2025, showcasing a 40% increase in revenue to £1.20 million, compared to £0.86 million in 2024. The Group's cash balance increased to £1.1 million, up from £0.9 million in the previous year. The adjusted EBITDA loss was £2.2 million, a decrease from the £2.8 million loss in 2024. Administration expenses also decreased to £2.9 million from £3.2 million. Post-period, the company completed a fundraising of £1.8 mi</description>
</item>
<item>
<title>New contract with top 10 pharma</title>
<link>https://6ix.com/company/aptamer-group-plc/news/new-contract-with-top-10-pharma</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/new-contract-with-top-10-pharma</guid>
<pubDate>Mon, 13 Oct 2025 06:00:00 GMT</pubDate>
<description>Aptamer Group PLC announced a new £112,000 fee-for-service contract with a top 10 global pharmaceutical company for Optimer binder development against two protein targets. This agreement, focused on biomarker research, builds upon previous successes and could lead to further ELISA development work. This contract brings the total contract value for FY26 to approximately £1.14 million, adding to the existing visibility of £1.03 million. The Group's fee-for-service pipeline stands at £3.3 million, </description>
</item>
<item>
<title>Notice of Results, Analyst & Investor Presentation</title>
<link>https://6ix.com/company/aptamer-group-plc/news/notice-of-results-analyst-and-investor-presentation-1</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/notice-of-results-analyst-and-investor-presentation-1</guid>
<pubDate>Fri, 10 Oct 2025 06:00:00 GMT</pubDate>
<description>Aptamer Group PLC will release its full year results for the year ended June 30, 2025, on Tuesday, October 14, 2025. An online briefing for analysts will be held at 9:30 am on the same day. Additionally, an investor presentation covering the full year results will take place at 2:00 pm on October 14, 2025, and is open to all existing and potential shareholders. Aptamer operates in the US$210 billion market for antibody alternatives.
Disclaimer*</description>
</item>
<item>
<title>Major top 3 global pharma contract win</title>
<link>https://6ix.com/company/aptamer-group-plc/news/major-top-3-global-pharma-contract-win</link>
<guid isPermaLink="true">https://6ix.com/company/aptamer-group-plc/news/major-top-3-global-pharma-contract-win</guid>
<pubDate>Wed, 08 Oct 2025 06:00:00 GMT</pubDate>
<description>Aptamer Group PLC announced a new £360,000 contract with a top 3 global pharmaceutical company for radiopharmaceutical development, retaining rights for future licensing revenues. The company has secured an additional £315,000 in new contracts and project extensions for the current financial year. Including the new development contract, Aptamer has secured additional commitments totaling £675,000 in total contract value. Combined with £350,000 of contract value carried over from FY25, this provi</description>
</item>
</channel>
</rss>